Actively Recruiting

Phase 3
Age: 18Years - 55Years
All Genders
NCT05906992

A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis

Led by Celltrion · Updated on 2024-05-22

512

Participants Needed

1

Research Sites

259 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This is a double-blind, randomized, active-controlled, parallel group, Phase 1/3 study to compare efficacy, PK, PD and overall safety of CT-P53 with Ocrevus in patients with Relapsing-remitting Multiple Sclerosis.

CONDITIONS

Official Title

A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis

Who Can Participate

Age: 18Years - 55Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Diagnosed with multiple sclerosis according to the revised McDonald criteria
  • Evidence of recent MS activity as defined in the study protocol
  • Neurological stability for at least 30 days
  • Expanded Disability Status Scale (EDSS) score between 0 and 6.0, inclusive
  • Age between 18 and 55 years
Not Eligible

You will not qualify if you...

  • Diagnosed with primary or secondary progressive multiple sclerosis
  • Diagnosed with MS for more than 15 years with an EDSS score of 2.0 or less at Screening
  • Unable to complete or having contraindications to an MRI scan
  • Contraindications or severe hypersensitivity to corticosteroids, methylprednisolone, study drug excipients, or related substances
  • History or presence of medical conditions described in the study protocol
  • Received or planned to receive prohibited medications or treatments as defined in the study protocol

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

CT-P53 3.1 investigational site

Poznan, Poland

Actively Recruiting

Loading map...

Research Team

S

SoYoung Yoo

CONTACT

J

JinHo Lee

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis | DecenTrialz